The U.S. Food and Drug administration has authorized the clinical trial of the lung cancer drug CIMAvax, according to New York Gov. Andrew Cuomo. He made the announcement at a news conference in the state capital Albany on Wednesday.
The trial will be conducted by Roswell Park Cancer Institute in Buffalo in partnership with Cuba's Centro de Inmunologia Molecular (CIM), CIMAvax's namesake.
CIMAvax is part of the next generation of cancer treatment called immunotherapy, which is a way of triggering the body's natural defences to attack cancer cells.
CIMAvax is already used on patients in Cuba with non-small cell lung cancer — reportedly costing as little as $1 to manufacture by one of Cuba's state biotech firms. FDA approval could clear the way for use in the U.S. and other markets.
Cuban lung cancer 'vaccine' gets FDA trial go-ahead - Health - CBC News
The trial will be conducted by Roswell Park Cancer Institute in Buffalo in partnership with Cuba's Centro de Inmunologia Molecular (CIM), CIMAvax's namesake.
CIMAvax is part of the next generation of cancer treatment called immunotherapy, which is a way of triggering the body's natural defences to attack cancer cells.
CIMAvax is already used on patients in Cuba with non-small cell lung cancer — reportedly costing as little as $1 to manufacture by one of Cuba's state biotech firms. FDA approval could clear the way for use in the U.S. and other markets.
Cuban lung cancer 'vaccine' gets FDA trial go-ahead - Health - CBC News
